How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 56.1 | 56.1 | 57.0 | 54.5 | 54.5 | 53.4 | -2.7 |
| Healthcare | 29.8 | 29.8 | 29.0 | 32.0 | 32.0 | 32.7 | +2.9 |
| Chemicals | 8.1 | 8.1 | 9.2 | 8.8 | 8.8 | 9.1 | +1.0 |
| Unclassified | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | -0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 11.18% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| ACUTAAS | Chemicals | 6.35% | 8 | 10 | 2 | 5 | 1 | 0/2 | +43.1% |
| DIVISLAB | Pharma | 5.92% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| APOLLOHOSP | Healthcare | 5.21% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| MAXHEALTH | Healthcare | 5.08% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| AUROPHARMA | Pharma | 4.17% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| ASTERDM | Healthcare | 3.77% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| LAURUSLABS | Pharma | 3.64% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| CIPLA | Pharma | 3.52% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| TORNTPHARM | Pharma | 3.33% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| BIOCON | Pharma | 3.14% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| GLAND | Pharma | 3.00% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| FORTIS | Healthcare | 2.87% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| MANKIND | Pharma | 2.85% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| ANTHEM | Pharma | 2.84% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| SAILIFE | Healthcare | 2.47% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| KIMS | Healthcare | 2.17% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| POLYMED | Healthcare | 2.16% | 5 | 6 | 6 | 6 | 5 | 0/2 | +9.3% |
| AJANTPHARM | Pharma | 2.05% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| COHANCE | Healthcare | 2.01% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
| LUPIN | Pharma | 1.94% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| CONCORDBIO | Pharma | 1.84% | 5 | 4 | 2 | 1 | 4 | 0/2 | +19.8% |
| MEDANTA | Healthcare | 1.47% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| ABBOTINDIA | Pharma | 1.22% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| LALPATHLAB | Healthcare | 0.99% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| RAINBOW | Healthcare | 0.85% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹214 (+114%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 140 vs Nifty 50 and 126 vs Nifty 500 — above 100, sustained outperformance.